-
Je něco špatně v tomto záznamu ?
Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients
R. Karlíková, J. Široká, D. Friedecký, E. Faber, M. Hrdá, K. Mičová, I. Fikarová, A. Gardlo, H. Janečková, I. Vrobel, T. Adam,
Journal of proteome research.
2016 ;
15 (9) :
3158-66.
[pub] 20160809
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc18017134
- MeSH
- aminokyseliny metabolismus MeSH
- chronická myeloidní leukemie krev metabolismus MeSH
- citrátový cyklus účinky léků MeSH
- glykolýza účinky léků MeSH
- hydroxymočovina farmakologie terapeutické užití MeSH
- imatinib mesylát farmakologie terapeutické užití MeSH
- inhibitory proteinkinas farmakologie MeSH
- krevní plazma chemie metabolismus MeSH
- leukocyty chemie metabolismus MeSH
- lidé MeSH
- metabolom * MeSH
- metabolomika metody MeSH
- monitorování léčiv metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The discovery of tyrosine kinase inhibitors (TKIs) brought a major breakthrough in the treatment of patients with chronic myeloid leukemia (CML). Pathogenetic CML events are closely linked with the Bcr-Abl protein with tyrosine kinase activity. TKIs block the ATP-binding site; therefore, the signal pathways leading to malignant transformation are no longer active. However, there is limited information about the impact of TKI treatment on the metabolome of CML patients. Using liquid chromatography mass spectrometric metabolite profiling and multivariate statistical methods, we analyzed plasma and leukocyte samples of patients newly diagnosed with CML, patients treated with hydroxyurea and TKIs (imatinib, dasatinib, nilotinib), and healthy controls. The global metabolic profiles clearly distinguished the newly diagnosed CML patients and the patients treated with hydroxyurea from those treated with TKIs and the healthy controls. The major changes were found in glycolysis, the citric acid cycle, and amino acid metabolism. We observed differences in the levels of amino acids and acylcarnitines between those patients responding to imatinib treatment and those who were resistant to it. According to our findings, the metabolic profiling may be potentially used as an additional tool for the assessment of response/resistance to imatinib.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017134
- 003
- CZ-PrNML
- 005
- 20180515103231.0
- 007
- ta
- 008
- 180515s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jproteome.6b00356 $2 doi
- 035 __
- $a (PubMed)27465658
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Karlíková, Radana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 245 10
- $a Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients / $c R. Karlíková, J. Široká, D. Friedecký, E. Faber, M. Hrdá, K. Mičová, I. Fikarová, A. Gardlo, H. Janečková, I. Vrobel, T. Adam,
- 520 9_
- $a The discovery of tyrosine kinase inhibitors (TKIs) brought a major breakthrough in the treatment of patients with chronic myeloid leukemia (CML). Pathogenetic CML events are closely linked with the Bcr-Abl protein with tyrosine kinase activity. TKIs block the ATP-binding site; therefore, the signal pathways leading to malignant transformation are no longer active. However, there is limited information about the impact of TKI treatment on the metabolome of CML patients. Using liquid chromatography mass spectrometric metabolite profiling and multivariate statistical methods, we analyzed plasma and leukocyte samples of patients newly diagnosed with CML, patients treated with hydroxyurea and TKIs (imatinib, dasatinib, nilotinib), and healthy controls. The global metabolic profiles clearly distinguished the newly diagnosed CML patients and the patients treated with hydroxyurea from those treated with TKIs and the healthy controls. The major changes were found in glycolysis, the citric acid cycle, and amino acid metabolism. We observed differences in the levels of amino acids and acylcarnitines between those patients responding to imatinib treatment and those who were resistant to it. According to our findings, the metabolic profiling may be potentially used as an additional tool for the assessment of response/resistance to imatinib.
- 650 _2
- $a aminokyseliny $x metabolismus $7 D000596
- 650 _2
- $a citrátový cyklus $x účinky léků $7 D002952
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 _2
- $a glykolýza $x účinky léků $7 D006019
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydroxymočovina $x farmakologie $x terapeutické užití $7 D006918
- 650 _2
- $a imatinib mesylát $x farmakologie $x terapeutické užití $7 D000068877
- 650 _2
- $a chronická myeloidní leukemie $x krev $x metabolismus $7 D015464
- 650 _2
- $a leukocyty $x chemie $x metabolismus $7 D007962
- 650 12
- $a metabolom $7 D055442
- 650 _2
- $a metabolomika $x metody $7 D055432
- 650 _2
- $a krevní plazma $x chemie $x metabolismus $7 D010949
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Široká, Jitka $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Friedecký, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Faber, Edgar $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Hrdá, Marcela $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Mičová, Kateřina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Fikarová, Iveta $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Gardlo, Alžběta $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic. Department of Mathematical Analysis and Applications of Mathematics, Palacký University Olomouc , 17. Listopadu 12, 771 46 Olomouc, Czech Republic.
- 700 1_
- $a Janečková, Hana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Vrobel, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Adam, Tomáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc , Hněvotínská 5, 779 00 Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc , I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 773 0_
- $w MED00166892 $t Journal of proteome research $x 1535-3907 $g Roč. 15, č. 9 (2016), s. 3158-66
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27465658 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515103405 $b ABA008
- 999 __
- $a ok $b bmc $g 1300758 $s 1013974
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 15 $c 9 $d 3158-66 $e 20160809 $i 1535-3907 $m Journal of proteome research $n J Proteome Res $x MED00166892
- LZP __
- $a Pubmed-20180515
